Home Tags Oncology

Tag: Oncology

Are Small-Format Drug Conjugates a Viable ADC Alternative Solid Tumors?

Antibody-drug conjugates or ADCs are complex immunoconjugates. They are designed to selectively deliver a small-molecules cytotoxic payload to cancer cells. Directed to specific tumor...

The Clinical Landscape of Antibody-drug Conjugates

Antibody drug conjugates (ADCs) are a class of therapeutics that combine the selective targeting properties of monoclonal antibodies (mAbs) with potent cell killing activities of cytotoxic agents. Given rapid pace of progress in this field, it is important for drug developers to have a high level view of the landscape of ADCs in the clinic. This review analyzes ADCs tested in the field of Oncology. Trials are evaluated by cancer type, trial status, phase, and characteristics of the ADC.

Brentuximab Vedotin Shows 42% Objective Response Rate in Patients with Relapsed...

New, updated, data from a phase II clinical trial of brentuximab vedotin (Adcetris®; Seattle Genetics) in patients with diffuse large B-cell lymphoma or DLBCL and other B-cell non-Hodgkin lymphomas, demonstrated an encouraging activity and tolerability profile in the relapsed and refractory setting. The results were presented at the 55th annual meeting of ASH®, the American Society of Hematology, held in New Orleans, Louisiana, USA, from December 7 - 10, 2013.
EORTC/GIMEA

EORTC/GIMEA Trial Does Not Show Benefits for Older AML Patients

Results of a randomized phase III trial evaluating the efficacy and toxicity of sequential gemtuzumab ozogamicin (GO) and standard chemotherapy provides no benefit in...

From the Editors: Welcome to a New Publication – ADC Review/Journal...

Welcome to ADC Review, Journal of Antibody-Drug Conjugates, a new online, peer-reviewed, open-access hybrid publication for those involved in the ongoing--and exciting--development of antibody-drug...

Majority of Pediatric Patients with Hodgkin Lymphoma Achieve CR After Treatment...

Six out of nine pediatric patients with relapsed or refractory Hodgkin lymphoma (HL) (n=5)or systemic anaplastic large cell lymphoma (sALCL) (n=4)achieved complete remission (CR)...

Brentuximab Offers Promising New Treatment Option for Patients with Relapsed or...

While 70 to 80% of all newly diagnosed patients with adult Hodgkin lymphoma are typically cured with combination chemotherapy of three or four agents...

DOWNLOAD